These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36151444)

  • 21. Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery.
    Keating GM
    Drugs; 2009 Jun; 69(9):1267-86. PubMed ID: 19537841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro-In Vivo Correlation Using In Silico Modeling of Physiological Properties, Metabolites, and Intestinal Metabolism.
    Choi SM; Kang CY; Lee BJ; Park JB
    Curr Drug Metab; 2017; 18(11):973-982. PubMed ID: 29086683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Fluoroquinolone-Based Antibacterial Ophthalmic Solutions on Corneal Wound Healing.
    Fukuda M; Sasaki H
    J Ocul Pharmacol Ther; 2015 Nov; 31(9):536-40. PubMed ID: 26186125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.
    Firsov AA; Vostrov SN; Lubenko IY; Drlica K; Portnoy YA; Zinner SH
    Antimicrob Agents Chemother; 2003 May; 47(5):1604-13. PubMed ID: 12709329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Terminalia arjuna gum/alginate in situ gel system with prolonged retention time for ophthalmic drug delivery.
    Noreen S; Ghumman SA; Batool F; Ijaz B; Basharat M; Noureen S; Kausar T; Iqbal S
    Int J Biol Macromol; 2020 Jun; 152():1056-1067. PubMed ID: 31751751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of the Plausible Mechanism of Ethambutol Induced Ocular Toxicity by Using Proteomics Informed Physiologically Based Pharmacokinetic (PBPK) Modeling.
    Balhara A; Ladumor MK; Nankar RP; Syed SD; Giri S; Prasad B; Singh S
    Pharm Res; 2022 Apr; 39(4):677-689. PubMed ID: 35301670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corneal wound healing in New Zealand White Rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%.
    Williams KK; Shepard AR; Rice RL; McCartney MD; Wax MB; Hiddemen JW
    J Ocul Pharmacol Ther; 2007 Dec; 23(6):517-25. PubMed ID: 18001231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma.
    Sousa J; Alves G; Campos G; Fortuna A; Falcão A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jul; 930():104-11. PubMed ID: 23727874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanism of fluoroquinolones modulation on corneal fibroblast motility.
    Chen TC; Tsai TY; Chang SW
    Exp Eye Res; 2016 Apr; 145():10-16. PubMed ID: 26546726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation.
    Bhalerao H; Koteshwara KB; Chandran S
    AAPS PharmSciTech; 2019 Aug; 20(7):272. PubMed ID: 31372767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic Modeling of In Vitro Skin Permeation and Extrapolation to In Vivo for Topically Applied Metronidazole Drug Products Using a Physiologically Based Pharmacokinetic Model.
    Arora S; Clarke J; Tsakalozou E; Ghosh P; Alam K; Grice JE; Roberts MS; Jamei M; Polak S
    Mol Pharm; 2022 Sep; 19(9):3139-3152. PubMed ID: 35969125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
    Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
    Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment.
    Knaak JB; Dary CC; Zhang X; Gerlach RW; Tornero-Velez R; Chang DT; Goldsmith R; Blancato JN
    Rev Environ Contam Toxicol; 2012; 219():1-114. PubMed ID: 22610175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.
    Li M; Zou P; Tyner K; Lee S
    AAPS J; 2017 Jan; 19(1):26-42. PubMed ID: 27834047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.
    Margolskee A; Darwich AS; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Laplanche L; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
    Eur J Pharm Sci; 2017 Jan; 96():610-625. PubMed ID: 27816631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel in vivo rabbit model that mimics human dosing to determine the distribution of antibiotics in ocular tissues.
    Owen GR; Brooks AC; James O; Robertson SM
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):335-42. PubMed ID: 17803431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
    Kesisoglou F; Xia B; Agrawal NG
    AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.